Verrica Pharmaceuticals Inc.'s next confirmed earnings release is scheduled for March 4, 2027.
| Earnings Date | 3/4/2027 |
As of June 30, 2026, Verrica Pharmaceuticals Inc. has 17.18M shares outstanding.
| Shares Outstanding | 17.18M |
As of June 30, 2026, Verrica Pharmaceuticals Inc. maintains a current ratio of 1.45, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.02, indicating elevated leverage, while an interest coverage ratio of -7.40 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.45 |
| Quick Ratio | 0.99 |
| Debt / Equity | 42.02 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | -7.40 |
These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -83.02, reflecting losses generated across the asset base. The company generates approximately 355,049.78 in revenue per employee across its workforce of 74.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.63 indicates how many times Verrica Pharmaceuticals Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -83.02 |
| Revenue Per Employee | 355,049.78 |
| Employee Count | 74.75 |
| Inventory Turnover | 1.63 |
Over the twelve months ended June 30, 2026, Verrica Pharmaceuticals Inc. generated 26.54M in revenue and converted that into -27.29M in net income, yielding earnings per share of -1.65. EBITDA reached -24.16M, while operating income came in at -23.14M.
| Revenue | 26.54M |
| Gross Profit | 22.80M |
| Operating Income | -23.14M |
| Pretax Income | -27.29M |
| Net Income | -27.29M |
| EBITDA | -24.16M |
| EBIT | -24.84M |
| Earnings Per Share (EPS) | -1.65 |
As of June 30, 2026, Verrica Pharmaceuticals Inc. holds 9.80M in cash and equivalents against 1.58M in total debt, resulting in a net debt position of -9.80M. Total book value stands at 3.77M, with working capital of 8.93M providing operational flexibility.
| Cash & Cash Equivalents | 9.80M |
| Total Debt | 1.58M |
| Net Debt | -9.80M |
| Equity (Book Value) | 3.77M |
| Book Value Per Share | 0.22 |
| Working Capital | 8.93M |
Verrica Pharmaceuticals Inc. produced -11.68M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -11.68M - equivalent to -0.71 per share.
| Operating Cash Flow | -11.68M |
| Free Cash Flow | -11.68M |
| FCF Per Share | -0.71 |
Over the twelve months ended June 30, 2026, Verrica Pharmaceuticals Inc. posted a gross margin of 85.89, reflecting its pricing power and cost economics. The operating margin of -87.18 and net profit margin of -102.84 provide insight into operational efficiency.
| Gross Margin | 85.89 |
| Operating Margin | -87.18 |
| Pretax Margin | -102.84 |
| Profit Margin | -102.84 |
| EBITDA Margin | -91.03 |
Verrica Pharmaceuticals Inc.'s most recent stock split took place on July 25, 2025 with a 10:1 split ratio.
| Last Split Date | 7/25/2025 |
| Split Ratio | 10:1 |